Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Amgen, Inc.    AMGN   US0311621009

AMGEN, INC. (AMGN)

136
Delayed Quote. Delayed Nasdaq - 10/31 04:00:02 pm
162.18 USD   +0.37%
2d ago AMGEN : Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion and..
3d ago Wall St. jumps 1 percent, S&P ends above key level
3d ago AMGEN : plans more job cuts, higher dividend
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

04/24/2012 | 05:40pm US/Eastern

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Latest news on AMGEN, INC.
12h ago AMGEN : Xencor Regains Rights to XmAb5871
2d ago AMGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
2d ago Establishment of GPCR Consortium, a New International Partnership, to Advance..
2d ago AMGEN : Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion and Adju..
3d ago Wall St. jumps 1 percent, S&P ends above key level
3d ago AMGEN : To Lay Off 274 Employees Puget Sound Region
3d ago AMGEN : plans more job cuts, higher dividend
3d ago AMGEN : US stocks rising as investors await Fed meeting
3d ago Pfizer beats sales and profit forecasts, mum on future deals
3d ago AMGEN : Costs Associated with Exit or Disposal Activities (form 8-K)
Advertisement
Chart
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF